Many thanks to the LSI Team for your recognition and for providing a platform to network within our industry!
EBAMed (#LSIUSA24 Innovator) is a Swiss start-up with a mission to develop solutions for the non-invasive treatment of cardiac arrhythmias. The company has developed an innovative Image-Guidance system that allows for the handling of cardiac motion during cardiac radioablation procedures. This system enables more precise irradiation of the cardiac target, minimizing the radiotherapy dose. As a result, it reduces toxicity to other parts of the heart (such as valves, coronary arteries), nearby lungs, and stomach. 🌟 EBAMed has achieved several significant milestones recently including: • Raised €14.35M in a Series A round led by #LSIAlumni Investor, Panakes Partners • Expanded its team, including the addition of Michael Cogswell as the new Chairman of the Board, Marlou Janssen as the Independent Expert of the Board, and Barbara Castellano as Director of the Board, while also strengthening its R&D team. • Successfully connected their Imaging Device with Radio Therapy Equipment from IBA Medical, Mevion, Varian, and Hitachi. • Obtained promising preclinical in-vivo data at UPenn showcasing the feasibility of synchronizing the beam to cardiac and respiratory cycles, paving the way for the first human clinical trial. • Built a robust patent portfolio, with 4 granted U.S. patents, 9 pending patent applications, 2 pending design applications, and continuation applications to further protect its technology. Congratulations to the EBAMed team on all of your recent success! We’re excited to announce that CEO, Marina Izzo, has been selected to present EBAMed at LSI USA ‘24 this March 18-22 in Dana Point, California. The presentation is scheduled for March 21st in Track 3.
EBAMed see you in a couple weeks!